BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...Wednesday TG closed at $19.18, up a further 15%. BerGenBio raises $48.7M in private placement BerGenBio ASA...
...round led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio...
BioCentury | May 2, 2020
Product Development

U.K. sets the bar for COVID-19 master protocols

...system is organized, the only way to access patients is through those programs.” Richard Godfrey, BerGenBio...
...most of the smaller studies that would otherwise enroll these patients. Richard Godfrey, CEO of BerGenBio ASA...
...compounds require. ACCORD is a Phase II/III study set to enroll 120 patients to receive BerGenBio’s...
BioCentury | Apr 30, 2020
Product Development

U.K.’s ACCORD platform trial to feed therapies into COVID-19 master protocols

...three so far disclosed. The first to be tested will be AXL inhibitor bemcentinib, which BerGenBio ASA...
...with the largest government health organization on the planet,” Richard Godfrey, CEO of cancer company BerGenBio...
...kinase Btk - Bruton’s tyrosine kinase IL-33 (NF-HEV) - Interleukin 33 Stephen Hansen, Associate Editor bemcentinib (BGB324, r428) BerGenBio ASA cov19count master...
BioCentury | Nov 21, 2018
Company News

Management tracks: BerGenBio, Alzamend

...Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) and CMO of Carrick Therapeutics Ltd. (Dublin, Ireland). Also on Wednesday, BerGenBio...
BioCentury | Sep 28, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

...tyrosine kinase (AXL; UFO). Keytruda is a PD-1 inhibitor from Merck & Co. Inc. (NYSE:MRK). BerGenBio...
...once-daily 200 mg oral bemcentinib plus Keytruda in 48 patients with previously treated advanced NSCLC. BerGenBio...
...NSCLC patients whose tumors express PD-L1 (≥1%) with disease progression on or after platinum-containing chemotherapy. BerGenBio ASA...
BioCentury | Sep 25, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

...tyrosine kinase (AXL; UFO). Keytruda is a PD-1 inhibitor from Merck & Co. Inc. (NYSE:MRK). BerGenBio...
...once-daily 200 mg oral bemcentinib plus Keytruda in 48 patients with previously treated advanced NSCLC. BerGenBio...
...NSCLC patients whose tumors express PD-L1 (≥1%) with disease progression on or after platinum-containing chemotherapy. BerGenBio...
BioCentury | Jun 28, 2018
Distillery Therapeutics

Cancer

...steps could include testing the compounds in additional models of breast cancer. Rigel Pharmaceuticals Inc., BerGenBio ASA...
...inhibitor, in Phase II testing for adenocarcinoma of the lung and metastatic TNBC. Rigel and BerGenBio...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Biotherapeutics Inc. (NASDAQ:IOVA) $12.65 -13% ImmunoGen Inc. (NASDAQ:IMGN) $10.01 -13% Immutep Ltd. (NASDAQ:IMMP) $2.49 -16% BerGenBio ASA...
BioCentury | Jun 8, 2018
Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

...response. The open-label, Norwegian trial, which is sponsored by Haukeland University Hospital in collaboration with BerGenBio...
...metastatic melanoma. Bemcentinib is a small molecule inhibitor of AXL receptor tyrosine kinase (AXL; UFO). BerGenBio...
...1 (MAP2K1; MEK1) and MAP2K2 (MEK2), and Tafinlar is an oral BRAF protein kinase inhibitor. BerGenBio ASA...
BioCentury | Jun 8, 2018
Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

...is evaluating the combination in about 48 patients with previously treated advanced NSCLC. Last year, BerGenBio...
...the trial. Bemcentinib is a small molecule inhibitor of AXL receptor tyrosine kinase (AXL; UFO). BerGenBio...
...exclusive, worldwide rights to the product from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) under a 2011 deal. BerGenBio ASA...
Items per page:
1 - 10 of 46
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...Wednesday TG closed at $19.18, up a further 15%. BerGenBio raises $48.7M in private placement BerGenBio ASA...
...round led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio...
BioCentury | May 2, 2020
Product Development

U.K. sets the bar for COVID-19 master protocols

...system is organized, the only way to access patients is through those programs.” Richard Godfrey, BerGenBio...
...most of the smaller studies that would otherwise enroll these patients. Richard Godfrey, CEO of BerGenBio ASA...
...compounds require. ACCORD is a Phase II/III study set to enroll 120 patients to receive BerGenBio’s...
BioCentury | Apr 30, 2020
Product Development

U.K.’s ACCORD platform trial to feed therapies into COVID-19 master protocols

...three so far disclosed. The first to be tested will be AXL inhibitor bemcentinib, which BerGenBio ASA...
...with the largest government health organization on the planet,” Richard Godfrey, CEO of cancer company BerGenBio...
...kinase Btk - Bruton’s tyrosine kinase IL-33 (NF-HEV) - Interleukin 33 Stephen Hansen, Associate Editor bemcentinib (BGB324, r428) BerGenBio ASA cov19count master...
BioCentury | Nov 21, 2018
Company News

Management tracks: BerGenBio, Alzamend

...Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) and CMO of Carrick Therapeutics Ltd. (Dublin, Ireland). Also on Wednesday, BerGenBio...
BioCentury | Sep 28, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

...tyrosine kinase (AXL; UFO). Keytruda is a PD-1 inhibitor from Merck & Co. Inc. (NYSE:MRK). BerGenBio...
...once-daily 200 mg oral bemcentinib plus Keytruda in 48 patients with previously treated advanced NSCLC. BerGenBio...
...NSCLC patients whose tumors express PD-L1 (≥1%) with disease progression on or after platinum-containing chemotherapy. BerGenBio ASA...
BioCentury | Sep 25, 2018
Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

...tyrosine kinase (AXL; UFO). Keytruda is a PD-1 inhibitor from Merck & Co. Inc. (NYSE:MRK). BerGenBio...
...once-daily 200 mg oral bemcentinib plus Keytruda in 48 patients with previously treated advanced NSCLC. BerGenBio...
...NSCLC patients whose tumors express PD-L1 (≥1%) with disease progression on or after platinum-containing chemotherapy. BerGenBio...
BioCentury | Jun 28, 2018
Distillery Therapeutics

Cancer

...steps could include testing the compounds in additional models of breast cancer. Rigel Pharmaceuticals Inc., BerGenBio ASA...
...inhibitor, in Phase II testing for adenocarcinoma of the lung and metastatic TNBC. Rigel and BerGenBio...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Biotherapeutics Inc. (NASDAQ:IOVA) $12.65 -13% ImmunoGen Inc. (NASDAQ:IMGN) $10.01 -13% Immutep Ltd. (NASDAQ:IMMP) $2.49 -16% BerGenBio ASA...
BioCentury | Jun 8, 2018
Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

...response. The open-label, Norwegian trial, which is sponsored by Haukeland University Hospital in collaboration with BerGenBio...
...metastatic melanoma. Bemcentinib is a small molecule inhibitor of AXL receptor tyrosine kinase (AXL; UFO). BerGenBio...
...1 (MAP2K1; MEK1) and MAP2K2 (MEK2), and Tafinlar is an oral BRAF protein kinase inhibitor. BerGenBio ASA...
BioCentury | Jun 8, 2018
Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

...is evaluating the combination in about 48 patients with previously treated advanced NSCLC. Last year, BerGenBio...
...the trial. Bemcentinib is a small molecule inhibitor of AXL receptor tyrosine kinase (AXL; UFO). BerGenBio...
...exclusive, worldwide rights to the product from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) under a 2011 deal. BerGenBio ASA...
Items per page:
1 - 10 of 46